Results 141 to 150 of about 22,609,350 (346)

Monoclonal Antibodies to CTLA-4 with Focus on Ipilimumab [PDF]

, 2013
Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4 or CD152) is a negative regulator of T-cell mediated immune responses, which plays a critical role in suppressing autoimmunity and maintaining immune homeostasis. Because of its inhibitory activity on T cells, CTLA-4 has been investigated as a drug target to induce immunostimulation, blocking the ...
GRAZIANI, GRAZIA, TENTORI, LUCIO, Navarra, P.   +2 more
openaire   +2 more sources

CTLA-4 expression, regulation and associations in autoimmune myasthenia gravis

, 2003
Myasthenia gravis (MG) is a neuromuscular disease with muscle weakness due to an autoimmune attack against the nicotinic acetylcholine receptor (nAChR) on the skeletal muscle endplate.
XiongBiao Wang (19494277)
core  

Tackling cancer stemness with nanotechnology in the era of precision medicine

BMEMat, EarlyView.
Precise customization of nanoparticles (NPs) enables active targeting of cancer stem cells (CSCs), thereby improving drug delivery and therapeutic efficacy. NP‐based probing enhances CSC detection through imaging and liquid biopsy, whereas diverse therapeutic payloads improve therapeutic outcomes.
Shaolei Guo, Shun Yao, Lihui Meng, Chunyuan Chen, Yuechu Lucinda Lu, Rong Lu, Kashif Rafiq Zahid, Umar Raza, Qingzhi Wu, Wenli Chen   +9 more
wiley   +1 more source

Toxicological and pharmacological assessment of AGEN1884, a novel human IgG1 anti-CTLA-4 antibody

, 2018
CTLA-4 and CD28 exemplify a co-inhibitory and co-stimulatory signaling axis that dynamically sculpts the interaction of antigen-specific T cells with antigen-presenting cells.
Nicholas S Wilson, Robert Stein, Taha Merghoub (217303), Andrea Schuster (3861352), Jedd D Wolchok, Mariana Manrique (5058668), Jennifer S Buell, Christopher Clarke (2849210), Jeremy D. Waight (195980), Elise E. Drouin (5058647), David Savitsky, Randi B. Gombos, David Schaer (5058644), Hao Tang, Christopher Dupont (815109), Benjamin Morin, Jennifer S. Buell, Mark A Findeis, Cornelia Mundt (5058659), Ekaterina Breous-Nystrom (5058638), Cornelia Mundt, Marc van Dijk (18075), Dhan Chand, Christopher Clarke, Dennis Underwood (5058656), Dhan Chand (5058662), Rebecca A Ward, Jedd D. Wolchok, Jennifer S. Buell (5058641), Ana Gonzalez (77722), Hao Tang (44155), Elise E. Drouin, Nicholas S. Wilson, Gerd Ritter (209869), Ana Gonzalez, Jeremy D Waight, Jedd D. Wolchok (217325), Andrea Schuster, Rebecca A. Ward, Benjamin Duckless (5058653), Christopher Dupont, Benjamin Duckless, Taha Merghoub, Jean-Marie Cuillerot (5058671), Randi B. Gombos (5058665), Benjamin Morin (241832), Dennis Underwood, David Savitsky (5058650), Jean-Marie Cuillerot, David Schaer, Jeremy D. Waight, Mark A. Findeis (2020771), Elise E Drouin, Ekaterina Breous-Nystrom, Robert Stein (1704328), Randi B Gombos, Rebecca A. Ward (5058674), Nicholas S. Wilson (5058677), Mariana Manrique, Marc van Dijk, Mark A. Findeis, Gerd Ritter   +61 more
core   +1 more source

Living Microbial Drugs

Chemistry – A European Journal, EarlyView.
The introduction outlines the review scope. Microbial cell factories as living drugs cover host–gut microbiota, bacteria, yeast, and other microbial systems, with comparative host advantages. Engineering strategies include synthetic circuits, quorum sensing, and memory.
Cemile Elif Özçelik, Nazlıcan Tunç, Senem Şen, Urartu Özgür Şafak Şeker   +3 more
wiley   +1 more source

Supplementary Material from In silico simulation of a clinical trial with anti-CTLA-4 and anti-PD-L1 immunotherapies in metastatic breast cancer using a systems pharmacology model

, 2019
Supplemental figures and tables can be found in Supplementary Material: anti-CTLA-4 monotherapy and combination therapy using high doses of tremelimumab; anti-CTLA-4 monotherapy and combination therapy using continuous doses of tremelimumab; waterfall ...
Hanwen Wang (6008003), Paolo Vicini (2311993), Rajesh Narwal (4425985), Aleksander S. Popel (134255), Bing Wang (126120), Lorin Roskos (4376230), Oleg Milberg (4425988), Imke H. Bartelink (6178610), Cesar A. Santa-Maria (6679424)   +8 more
core   +2 more sources

Vitamin D Antagonises the Suppressive Effect of Inflammatory Cytokines on CTLA-4 Expression and Regulatory Function.

PLoS ONE, 2015
The immune suppressive protein CTLA-4 is constitutively expressed by Tregs and induced in effector T cells upon activation. Its crucial role in adaptive immunity is apparent from the fatal autoimmune pathology seen in CTLA-4 knockout mice.
Louisa E Jeffery, Omar S Qureshi, David Gardner, Tie Z Hou, Zoe Briggs, Blagoje Soskic, Jennifer Baker, Karim Raza, David M Sansom   +8 more
doaj   +1 more source

CTLA-4: un receptor inhibidor de los linfocitos T

, 2019
CTLA-4 es un homólogo de CD28 expresado en la superficie de los linfocitos T. CTLA-4 está expresado transitoriamente en la superficie de células T CD8 activadas tempranamente; sin embargo, su expresión es constitutiva en las T-reguladoras.
Anduaga Armenia, Mario Armando
core   +1 more source

Network describing the interactions among cells and cytokines under treatment with anti-PD-1, anti-CTLA-4, ENZ and Sip-T.

, 2022
Network describing the interactions among cells and cytokines under treatment with anti-PD-1, anti-CTLA-4, ENZ and Sip-T.
Nourridine Siewe (5081834), Avner Friedman (54903)   +1 more
core   +1 more source

Carbon Dots for Cancer Theranostics: Synthesis Strategies, Luminescence Properties, and Advances in Bioimaging‐Guided Diagnosis and Therapy

Chemistry – A European Journal, EarlyView.
Lighting up the path to precision oncology: This review comprehensively summarizes the rational design of carbon dots (CDs), elucidating how core size, surface chemistry, and heteroatom doping dictate their luminescence mechanisms. Special emphasis is placed on engineering NIR‐II emissive CDs for deep‐tissue imaging.
Zekun Yan, Yupeng Liu, Jinyun Tan, Songnan Qu   +3 more
wiley   +1 more source